Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Ultrasonographic Predictors of Adductor Canal Block Effectiveness in Total Knee Arthroplasty

NCT07730216 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-08-09
Last updated
2026-08-12

Condition(s) studied

Arthroplasty, Replacement, KneeNerve Block AssessmentPain, Postoperative Arthroscopy

Investigational drug(s) / intervention(s)

Adductor Canal Block (ACB) Only

Adductor Canal Block (ACB) Only: The adductor canal block (ACB) will be performed in the post-anesthesia care unit (PACU) after regression of spinal anesthesia.

Study summary

Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events \[1,2\]. Adductor canal block (ACB) has become a key component of enhanced recovery after surgery (ERAS) protocols because it provides effective anterior knee analgesia while largely preserving quadriceps muscle strength \[2-4\]. However, analgesic efficacy after ACB remains variable, and some patients require rescue opioid analgesia despite technically successful block placement \[5\]. Although ultrasound guidance improves block accuracy, factors such as tissue depth, anatomical variations, saphenous nerve visibility, and injectate spread pattern may influence clinical outcomes \[6,7\]. Prospective evidence regarding the predictive value of these ultrasound-derived parameters for ACB analgesic failure remains limited. Therefore, this study aims to evaluate whether preoperative ultrasound-derived tissue and target parameters-including skin-to-target depth, subcutaneous fat thickness, muscle thickness, saphenous nerve visibility, and injectate spread pattern-can predict ACB analgesic failure and early postoperative analgesic outcomes following TKA.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia * American Society of Anesthesiologists (ASA) physical status I-III Exclusion Criteria: * Daily opioid use or chronic pain syndrome * Diabetic or other clinically diagnosed peripheral neuropathy * Coagulopathy * Infection at the injection site * Known allergy or hypersensitivity to local anesthetics * Revision total knee arthroplasty * Conversion from spinal anesthesia to general anesthesia during surgery * General anesthesia as the planned anesthetic technique

Primary outcome measure(s)

  • ACB Failure — 0-24 hours
    ACB analgesic failure will be defined as the requirement for rescue analgesia during the first 24 hours after block administration, with intravenous tramadol (1 mg/kg) administered to patients with an NRS pain score ≥4.

Trial sites (1)

FacilityCityRegionStatus
Konya City Hospital Konya Konya Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07730216 on ClinicalTrials.gov ↗ ← All trials in Turkey